China SXT Pharmaceuticals (SXTC) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for China SXT Pharmaceuticals (SXTC) over the last 6 years, with Q3 2025 value amounting to $158263.0.

  • China SXT Pharmaceuticals' Total Non-Current Liabilities fell 4689.36% to $158263.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $158263.0, marking a year-over-year decrease of 4689.36%. This contributed to the annual value of $211683.0 for FY2025, which is 2816.2% down from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Total Non-Current Liabilities of $158263.0 as of Q3 2025, which was down 4689.36% from $211683.0 recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $365823.0 for Q1 2023, and its period low was $6292.0 during Q1 2021.
  • For the 4-year period, China SXT Pharmaceuticals' Total Non-Current Liabilities averaged around $235178.7, with its median value being $294667.0 (2024).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 8276.68% in 2021, then crashed by 433.4% in 2024.
  • Quarter analysis of 4 years shows China SXT Pharmaceuticals' Total Non-Current Liabilities stood at $6292.0 in 2021, then skyrocketed by 4850.92% to $311512.0 in 2023, then dropped by 4.33% to $298011.0 in 2024, then tumbled by 46.89% to $158263.0 in 2025.
  • Its Total Non-Current Liabilities stands at $158263.0 for Q3 2025, versus $211683.0 for Q1 2025 and $298011.0 for Q3 2024.